Evogene Ltd. (EVGN)
NASDAQ: EVGN · Real-Time Price · USD
1.180
-0.040 (-3.28%)
Nov 5, 2025, 4:00 PM EST - Market closed
Evogene Revenue
Evogene had revenue of $884.00K in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to $9.44M, up 42.25% year-over-year. In the year 2024, Evogene had annual revenue of $8.51M with 50.90% growth.
Revenue (ttm)
$9.44M
Revenue Growth
+42.25%
P/S Ratio
1.13
Revenue / Employee
$80,718
Employees
117
Market Cap
10.70M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 8.51M | 2.87M | 50.90% |
| Dec 31, 2023 | 5.64M | 3.97M | 236.72% |
| Dec 31, 2022 | 1.68M | 745.00K | 80.11% |
| Dec 31, 2021 | 930.00K | -110.00K | -10.58% |
| Dec 31, 2020 | 1.04M | 287.00K | 38.11% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
EVGN News
- 2 months ago - Evogene to Present at H.C. Wainwright 27th Annual Global Investment Conference in New York - PRNewsWire
- 2 months ago - Evogene Ltd. (EVGN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Evogene Reports Second Quarter 2025 Financial Results - PRNewsWire
- 3 months ago - Evogene and Professor Ehud Gazit of Tel Aviv University Announce a Collaboration to Develop New Therapeutics for Metabolic Diseases - PRNewsWire
- 3 months ago - Evogene Schedules Second Quarter 2025 Financial Results Release - PRNewsWire
- 4 months ago - Evogene Announces Completion of Transaction for the Sale of Lavie Bio's Activity to ICL - PRNewsWire
- 5 months ago - Evogene Announces Completion of First-In-Class Foundation Model for Generative Molecule Design, Developed in Collaboration with Google Cloud - PRNewsWire
- 6 months ago - Evogene Ltd. (EVGN) Q1 2025 Earnings Call Transcript - Seeking Alpha